COVID-19 Testing Solutions | Ortho Clinical Diagnostics

VITROS® COVID-19 TESTING SOLUTIONS

We've Delivered Five COVID-19 Tests With Emergency Use Authorizations (EUAs) Since April 2020

We are proud that more than 80 years of expertise fueled our ability to answer the call in record time when the world needed us most. We're only getting started.

OUR COVID-19 TESTING SOLUTIONS

Innovation and Agility Define Our COVID-19 Testing Solutions

When the world was faced with a pandemic, we didn't waste any time in answering the call and delivering quality COVID-19 testing solutions in record time so labs could meet the needs of their patients and communities.

We remain dedicated to meeting the ever-changing demands of the pandemic with reliable, high-throughput testing solutions for SARS‑CoV‑2 infection, antibody detection and antigen detection. Because Every Test Is A Life™

THE VITROS SARS‑CoV‑2 ANTIGEN TEST

Our antigen test is a high-throughput, highly accurate test that detects acute infection of SARS‑CoV‑2.

Learn more >

THREE QUALITATIVE ANTIBODY TESTS

Our VITROS COVID-19 Total and IgG Antibody Assays provide highly accurate and reliable detection of SARS‑CoV‑2 antibodies to help clinicians and researchers understand immune response. Our VITROS Anti-SARS‑CoV‑2 Total N antibody test is designed to capture total antibodies to the nucleocapsid protein.*

Learn more >

ANOTHER FIRST: THE VITROS® ANTI-SARS‑CoV‑2 IgG QUANTITATIVE TEST

We are helping labs quantify the level of COVID-19 antibodies for patients and individuals in their communities with the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA.

Learn more>

VITROS PERFORMANCE DASHBOARD

View productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help you make more informed decisions for your hospital and community.

See it in action >

THE ORTHO DIFFERENCE

The reliable testing solution you and your community can count on.

WE ARE AMONG THE FIRST TO OFFER BOTH SARS-CoV-2 INFECTION AND ANTIBODY TESTING ON THE SAME HIGH-THROUGHPUT IN-VITRO DIAGNOSTICS SYSTEM.

We have multiple VITROS COVID-19 Testing Solutions including the VITROS SARS-CoV-2 Antigen Test that can be run on the same high-throughput system with several antibody assays including a VITROS Anti-SARS-CoV-2 Total and Quantitative IgG Test that is designed to target the spike protein and the VITROS Anti-SARS-CoV-2 Total Test that is designed to target the nucleocapsid protein.*

*Available only in the U.S. market under Emergency Use Authorization with the U.S. Food and Drug Administration. Availability of assays varies by country.

Our proprietary VITROS Systems technology enables dynamic lab operation.

The waterless and fully automated VITROS Systems prepare your lab for maximum flexibility to respond to the needs of the pandemic.

Enabling technologies

Disposable tips, microsensor quality control, and INTELLICHECK^® Technology to reduce errors that work together to ensure you always get the most reliable results, every single time.

Easily reconfigure your labs

VITROS Systems don't require plumbing, which means you can adapt and enhance your lab’s workflow to the changing needs of the pandemic.

Less maintenance

Ready when you need it with 24-hour ready mode and long calibration intervals at 28 days.

Industry-leading service and support

Ortho Care® Service and Support is #1 in service and virtual training, with a 98% uptime guarantee.*

*Ortho Care® holistic support program is #1 in service, virtual training, with a 98% uptime guarantee.

VITROS® COVID-19 Testing Solutions are more than just a tool for your lab — they help support your community.

Our COVID-19 Testing Solutions will:

Improve lab efficiency

High throughputs, short turnaround times, up-to-date data and easy-to-use automated systems will help improve the efficiency of your lab during this tumultuous time.

Provide expertise

The latest COVID-19 data and insights, fast, reliable results and our VITROS System’s unique technology will help position your hospital as a leader in your community during the pandemic.

Help stop the spread

Fast, reliable COVID-19 testing for both virus and antibody detection can help community leaders make informed decisions about public health.

Because Every Test Is A Life™

Our VITROS COVID-19 Testing Solutions are our newest way to help you overcome today’s challenges and provide better care for your patients and your community. All of our solutions, from COVID-19 and beyond, are designed with you and your patient in mind.

Are you ready for peace of mind?

Get the right results now.

More information

This website contains information that is targeted to a wide range of audiences and could contain product details or information otherwise not valid or applicable to your country. Consult your local legal restrictions, regulations, registrations or intended uses in your country of origin. Product availability may vary from country to country and is subject to varying regulatory requirements.
The VITROS Anti-SARS-CoV-2 IgG Quantitative, VITROS Anti-SARS-CoV-2 Total N Antibody, VITROS SARS-CoV-2 Antigen, VITROS Anti-SARS-CoV-2 Total and VITROS Anti-SARS-CoV-2 IgG Antibody Tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA).
The VITROS-SARS-CoV-2 Antigen Assay, VITROS Anti-SARS-CoV-2 Total N and and the VITROS Anti-SARS CoV-2 IgG Quantitative Tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). They have been authorized by the FDA under an Emergency Use Authorization (EUA) and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate- or high-complexity tests.
The VITROS SARS-CoV-2 Antigen, VITROS Anti-SARS-CoV-2 Total and VITROS Anti-SARS-CoV-2 IgG Antibody Tests and VITROS Anti-SARS-CoV-2 IgG have been authorized by the FDA under an Emergency Use Authorization and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests.
The VITROS Antibody tests have been authorized only for the detection of either Total or IgG antibodies from SARS-CoV-2, not for any other viruses or pathogens, and results should not be used as the sole basis for diagnosis. The VITROS Antigen test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.